Conatus
A biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.
Based in San Diego, USA, the company is developing its lead in-licensed compound, emricasan (in collaboration with Novartis), for the treatment of patients with NASH-driven chronic liver diseases.
Conatus is also independently developing its lead internally developed compound, CTS-2090, for the treatment of patients with chronic diseases involving inflammasome pathways.
Latest Conatus News & Features
7 July 2023
30 June 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze